• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Resmed Names Salli Schwartz as Chief Investor Relations Officer

    4/21/25 5:00:00 PM ET
    $RMD
    Medical/Dental Instruments
    Health Care
    Get the next $RMD alert in real time by email

    SAN DIEGO, April 21, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE:RMD, ASX: RMD), ASX: RMD), the global leader in health technology focused on sleep, breathing, and care delivered in the home, today announced the appointment of Salli Schwartz as Chief Investor Relations Officer, effective April 21, 2025. In this role, Schwartz will lead Resmed's global investor relations function and report to Mick Farrell, Chairman of the Board and CEO.

    Schwartz is a seasoned executive with more than two decades of experience in a range of finance roles at health tech and financial services organizations. She joins Resmed from Illumina, Inc., where she served as the Head of Investor Relations. In that role, she led the company's investor engagement strategy, representing the company's response to shareholders' perspectives on corporate strategy, capital allocation, and financial performance. She was also a member of Illumina's Corporate Social Responsibility Executive Steering Committee and its Transformation Office.

    "Salli is a seasoned financial leader with a proven track record of driving investor relationships supporting business strategy and capital efficiency," said Farrell. "Her leadership and expertise will be critical as we advance our 2030 strategy to drive shareholder value and empower 500 million people worldwide to achieve their full health potential."

    Prior to Illumina, Schwartz served as Head of Investor Relations and Treasurer at MSCI, Inc., where she managed investor communications as well as a portfolio of over $2 billion in cash and short-term investments, and more than $4 billion in high-yield debt. She was also a member of MSCI's Corporate Responsibility Committee, Enterprise Risk Oversight Committee, and Investment Committee. Earlier in her career, Schwartz held multiple roles at Moody's Corporation, including Global Head of Strategic Capital Management and Treasurer, and Global Head of Investor Relations and Communications. She also worked in corporate strategy, corporate treasury, and FP&A with Citigroup Inc.

    "I am excited to join Resmed at such a pivotal moment in its strategy to make better sleep and breathing health more accessible around the world," said Schwartz. "I look forward to partnering with our leadership team and our shareholders to communicate and advance Resmed's vision and financial targets."

    About Resmed

    Resmed (NYSE:RMD, ASX: RMD)) creates life-changing health technologies that people love. We're relentlessly committed to pioneering innovative technology to empower millions of people in 140 countries to live happier, healthier lives. Our AI-powered digital health solutions, cloud-connected devices and intelligent software make home healthcare more personalized, accessible, and effective. Ultimately, Resmed envisions a world where every person can achieve their full potential through better sleep and breathing, with care delivered in their own home. Learn more about how we're redefining sleep health at Resmed.com and follow @Resmed.

    For Media: 

     For Investors:

       
    Kristen Handley Slater Mike Ott or Wendy Wilson
    [email protected]  [email protected]


    Primary Logo

    Get the next $RMD alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RMD

    DatePrice TargetRatingAnalyst
    3/19/2025$280.00Overweight
    Morgan Stanley
    3/19/2025Overweight
    Morgan Stanley
    1/16/2025Buy
    Goldman
    1/10/2025$252.00Neutral
    Piper Sandler
    12/13/2024$250.00Hold
    Stifel
    9/24/2024$280.00Outperform
    Robert W. Baird
    9/18/2024$180.00Peer Perform → Underperform
    Wolfe Research
    9/4/2024Buy → Hold
    Needham
    More analyst ratings

    $RMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Farrell Michael J. exercised 8,009 units of ResMed Common Stock at a strike of $101.64 and sold $2,011,910 worth of ResMed Common Stock (8,009 units at $251.21) (SEC Form 4)

      4 - RESMED INC (0000943819) (Issuer)

      6/10/25 6:35:44 PM ET
      $RMD
      Medical/Dental Instruments
      Health Care
    • Director Farrell Peter C sold $494,640 worth of ResMed Common Stock (2,000 units at $247.32), decreasing direct ownership by 3% to 69,218 units (SEC Form 4)

      4 - RESMED INC (0000943819) (Issuer)

      6/6/25 3:22:36 PM ET
      $RMD
      Medical/Dental Instruments
      Health Care
    • Chief Financial Officer Sandercock Brett sold $243,780 worth of ResMed Common Stock (1,000 units at $243.78), decreasing direct ownership by 1% to 85,283 units (SEC Form 4)

      4 - RESMED INC (0000943819) (Issuer)

      6/3/25 5:59:17 PM ET
      $RMD
      Medical/Dental Instruments
      Health Care

    $RMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Morgan Stanley initiated coverage on ResMed with a new price target

      Morgan Stanley initiated coverage of ResMed with a rating of Overweight and set a new price target of $280.00

      3/19/25 10:13:23 AM ET
      $RMD
      Medical/Dental Instruments
      Health Care
    • Morgan Stanley initiated coverage on ResMed

      Morgan Stanley initiated coverage of ResMed with a rating of Overweight

      3/19/25 8:18:03 AM ET
      $RMD
      Medical/Dental Instruments
      Health Care
    • Goldman initiated coverage on ResMed

      Goldman initiated coverage of ResMed with a rating of Buy

      1/16/25 7:53:14 AM ET
      $RMD
      Medical/Dental Instruments
      Health Care